B2BROKER Launches cTrader Support & Maintenance Service
14.2.2025 10:46:00 EET | Business Wire | Press release
B2BROKER, a leading liquidity and technology provider, has expanded its services with a new cTrader support and maintenance solution, complementing its existing MT4 and MT5 service offerings.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250211557945/en/
B2BROKER, a multi-asset liquidity and technology provider, announces the release of its cTrader support and maintenance service. The cTrader Service offers setup, ongoing maintenance, and comprehensive support for your cTrader server, saving you time and financial resources. (Graphic: Business Wire)
cTrader is a widely used multi-asset FOREX/CFD trading platform. Over 300 brokers use it, and adoption is expected to reach 80%. However, high maintenance costs and lengthy team training—often taking up to six months—can pose challenges for brokers.
B2BROKER’s cTrader service solution provides comprehensive technical support and expert dealing training, enabling brokers to streamline operations, reduce costs, and focus on growth.
Notably, clients with an existing cTrader server can benefit from a comprehensive audit service, including a full review of current settings, optimisation recommendations, and seamless transition preparation for B2BROKER’s maintenance.
Here’s a breakdown of the core features included in B2BROKER’s cTrader service:
- Platform configurations
- Server support
- Settings control
- Trading conditions changes
- Symbol sessions modification
- Logs review
Why Choose B2BROKER’s cTrader Service?
B2BROKER’s cTrader service offers a superior alternative to in-house management, providing brokers with expert support, cost savings, and seamless operations.
With extensive expertise in configuring and customising cTrader, B2BROKER’s specialists ensure faster setup, optimised performance, and reduced training requirements—far exceeding the capabilities of most internal teams. This allows brokers to streamline operations without the burden of additional staffing.
The service is also highly cost-effective, offering a more affordable solution than maintaining a full-time in-house team. Clients benefit from 24/7 support and continuous monitoring, ensuring platform stability and peak performance at all times.
B2BROKER takes full responsibility for server infrastructure, employing proactive measures and automated solutions to maintain system reliability and swiftly resolve any issues, keeping trading operations smooth and uninterrupted.
Other benefits of choosing B2BROKER include:
- Team of Market Experts: B2BROKER’s team is continuously on track with the most recent cTrader updates and best practices.
- On-call Systems: Customised support levels with proactive tools that guarantee the quickest resolution to any issue.
- Risk Management Assistance: B2BROKER offers advanced systems for setting risk limits on trading accounts and provides tailored suggestions to every business needs.
- Direct Communication: Brokers can enjoy direct communication channels with cTrader managers to efficiently deal with all necessary liaisons.
- Extended Knowledge Base: Clients can access valuable resources for continuous learning and support, including Zendesk Knowledge Base and a dedicated YouTube channel.
- Training Services: B2BROKER’s team will train the client’s technicians in all aspects of platform customisation and remain available for consultations.
One Solution That Suits All Business Models
B2BROKER recognises that every trading business has unique requirements. Therefore, whether a broker operates independently with cTrader technology or as a standalone entity, B2BROKER offers flexible service plans tailored to diverse business models, ensuring optimised performance and expert support.
“We’ve been in the trading technology field for over a decade, growing alongside our partners at Spotware, the creators of cTrader. We were among the first to launch a cTrader white label solution, and we've recently added a cTrader prop trading white label solution to our offerings. I'm proud to say that our long-standing relationship with Spotware's excellent team enables us to guarantee outstanding service.
“Let us take care of everything—from the setup to the daily management of your cTrader servers—so you can focus on achieving your business goals with confidence.”
Arthur Azizov, CEO & Founder of B2BROKER
Start with B2BROKER’s Professional cTrader Service
Choosing B2BROKER’s cTrader maintenance offers professional service to the trading platform, allowing brokers to focus on core business activities and ensuring that all operations are managed by comprehensive support and advanced tools.
Learn more about B2BROKER’s cTrader server service here.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250211557945/en/
Contacts
sales@B2BROKER.com
+44 208 068 8636
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Alnylam Presents New Data at ESC Congress 2026 Reinforcing Strength in RNAi-Powered TTR Silencing Across ATTR-CM Patient Populations and Treatment Settings30.8.2026 15:23:00 EEST | Press release
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced new data at the European Society of Cardiology (ESC) Congress 2026 demonstrating the strength of RNAi-powered silencing for cardiovascular disease. The findings further reinforce the clinical profile of AMVUTTRA® (vutrisiran) across transthyretin amyloidosis (ATTR) patient populations, treatment settings, and manifestations of disease. Additionally, the data expand the potential application of RNAi to uncontrolled hypertension, the world’s leading cause of cardiovascular disease. “With the power of our RNAi therapeutics platform, we have the potential to make a transformational impact on cardiovascular care,” said Pushkal Garg, M.D., Chief Research and Development Officer at Alnylam. “The data presented at ESC demonstrate the consistency of clinical outcomes achieved by RNAi-powered TTR silencing, reinforcing our conviction in AMVUTTRA as a first-line treatment option for ATTR-CM. With
New Auction Record Set as Falcon Sells for AED 1.5 Million at ADIHEX 202630.8.2026 00:54:00 EEST | Press release
Under the patronage of His Highness Sheikh Hamdan bin Zayed Al Nahyan, Ruler’s Representative in Al Dhafra Region and Chairman of the Emirates Falconers’ Club, the fifth auction held as part of the 23rd edition of the Abu Dhabi International Hunting and Equestrian Exhibition (ADIHEX) 2026 attracted remarkable turnout, culminating in the sale of a Qarmousha Pure Ultra White falcon for AED 1.5 million (USD 408,000). The sale marks the highest price achieved at any auction during this year’s edition of the exhibition. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260829032621/en/ Qarmousha Pure Ultra White (Photo: AETOSWire) This forms part of the largest auction programme in the exhibition’s history, held under the theme “A Legacy of Pride,” organised by ADNEC Group, a Modon company, in strategic partnership with the Emirates Falconers’ Club, at ADNEC Centre Abu Dhabi. The exhibition runs until 6 September. The falcon, owned
Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera29.8.2026 01:40:00 EEST | Press release
Takeda (TSE:4502/NYSE:TAK)announced U.S. Food and Drug Administration (FDA) approval of the New Drug Application (NDA)* for MIMRYLO™ (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a blood cancer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260824773270/en/ MIMRYLO Logo MIMRYLO is a first-in-class hepcidin mimetic designed to regulate iron distribution in the body and red blood cell overproduction to control hematocrit levels, which is the ratio of red blood cells to the total amount of blood in the body. Maintaining controlled hematocrit levels below 45% is the primary treatment goal in PV.1 “For patients living with PV, uncontrolled hematocrit can have serious consequences, including an elevated risk of life-threatening thrombotic events," said Andrew T. Kuykendall, M.D., VERIFY lead investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “Curre
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 17:00:00 EEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 16:34:00 EEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom